Table 3.
MBH | AP | ||||
---|---|---|---|---|---|
Sex | Group | Kd (nM) | Bmax (fmol (mg protein)−1) | Kd (nM) | Bmax (fmol (mg protein)−1) |
M | Sham ODX | 2.4 ± 0.3 | 82 ± 9 | 2.5 ± 0.2 | 30 ± 4 |
ODX | 2.2 ± 0.2 | 143 ± 16* | 2.4 ± 0.3 | 33 ± 5 | |
ODX + T | 2.5 ± 0.3 | 76 ± 8 | 2.5 ± 0.3 | 29 ± 3 | |
F | Sham OVX | 2.3 ± 0.3 | 213 + 27† | 2.3 ± 0.3 | 28 ± 4 |
OVX | 2.6 ± 0.4 | 130 ± 14‡ | 2.5 ± 0.3 | 31 ± 3 | |
OVX + E2 | 2.4 ± 0.3 | 260 ± 23‡ | 2.6 ± 0.2 | 32 ± 4 | |
OVX + P | 2.4 ± 0.2 | 135 ± 18‡ | 2.3 ± 0.2 | 33 ± 3 | |
OVX + E2 + P | 2.5 ± 0.2 | 220 ± 25† | 2.4 ± 0.2 | 34 ± 4 |
Six separate binding experiments were performed in each group. For abbreviations, see Tables 1 and 2 and Fig. 4.
Statistically significant vs. the other male groups.
Statistically significant vs. the OVX, OVX + P and the three male groups.
Statistically significant vs. the sham ODX and ODX + T groups.